Explore more publications!

Press Releases

ACA Pharma Announces Major Expansion of RYANODEX® Territory Outside the United States
Cell Culture Collagen Market to Attain USD 4.19 Billion by 2034, Driven by Expanding Healthcare Applications
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
Trends in Metallized Film Market 2025-2035
Berberine API Market to Reach USD 973.13 Million by 2034, Driven by Expanding Healthcare Applications
Iceland finds mosquitoes for first time after facing record heat

Iceland finds mosquitoes for first time after facing record heat

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
Wound Care Centers Market to Attain USD 64.49 Billion by 2034, Driven by Rising Disease Burden and Healthcare Innovations
Molecular Cloning Market to Attain USD 8.89 Billion by 2034, Driven by Expanding Healthcare Applications and Innovation
Orphan Drug Market to Reach USD 621.85 Billion by 2034, Driven by Rising Rare Disease Incidence and Innovation
High Concentration mAb Products Market Advancing Precision Biopharmaceutical Therapeutics – Towards Healthcare
Rapid Medical Diagnostic Kits Market to Surpass USD 61.42 Billion by 2034, Driven by Expanding Healthcare Applications and Rising Health Awareness
Protein Engineering Market to Grow at 16.27% CAGR by 2034, Driven by Rising Outsourcing and Expanding Healthcare Applications
NLP in Healthcare and Life Sciences Market Size Grows at 34.74% CAGR to Soar USD 132.34 Billion 2034
Why Poly-Woven Packaging Market Manufacturers are Successful
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
Investments in Colorless Polyimide Films Market for 2026
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
Alvotech announces planned CEO succession and leadership transition

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions